Home Publications Research Grants Inventions & Patents Awards Additional Research Activities Faculties & Institutions Research Areas

Prevalence and prognostic role of thoracic lymphadenopathy in Covid-19.

Sähn MJ, Wienke A, Meyer HJ, Dietz J, Vogl TJ, Borggrefe J, Gussew A, König A, Surov A, Bucher A, Mahnken A, Bücker A, Hamm B, Valentin B, Stroszczynski C, Kuhl C, Düber C, Kloth C, Kütting D, Maintz D, Kotter E, Bohrer E, Bamberg F, Güttler F, Meinel FG, Schwarz F, Wacker F, Kostka F, Krombach G, Antoch G, Adam G, Borte G, Kauczor HU, Winther H, Kleesiek J, Ricke J, Kühn JP, Lotz J, Barkhausen J, Peldschus K, Nikolaou K, Pech M, Sieren M, Weber MA, Both M, Makowski M, Fink M, Frölich M, May M, Beer M, Forsting M, Ingrisch M, Uder M, Hosten N, Hamer O, Jansen O, Isfort P, Kuhl PJ, Hoffmann RT, Braren R, Rischen R, Kloeckner R, Ahmed S, Afat S, Pätzholz S, Schönberg S, Kröncke T, Vogl T, Bley T, Persigehl T, Denecke T, Penzkofer T, Teichgräber U, Attenberger U, Nicolas V, Heindel W, Wohlgemuth W (2025)

---

Publication Type: Journal article

Publication year: 2025

Journal

Book Volume: 197

Pages Range: 163-171

Journal Issue: 2

DOI: 10.1055/a-2293-8132

Abstract

PURPOSE:  The prevalent coronavirus disease 2019 (COVID-19) pandemic has spread throughout the world and is considered a serious threat to global health. The prognostic role of thoracic lymphadenopathy in COVID-19 is unclear. The aim of the present meta-analysis was to analyze the prognostic role of thoracic lymphadenopathy for the prediction of 30-day mortality in patients with COVID-19. MATERIALS AND METHODS:  The MEDLINE library, Cochrane, and SCOPUS databases were screened for associations between CT-defined features and mortality in COVID-19 patients up to June 2021. In total, 21 studies were included in the present analysis. The quality of the included studies was assessed by the Newcastle-Ottawa Scale. The meta-analysis was performed using RevMan 5.3. Heterogeneity was calculated by means of the inconsistency index I2. DerSimonian and Laird random-effect models with inverse variance weights were performed without any further correction. RESULTS:  The included studies comprised 4621 patients. The prevalence of thoracic lymphadenopathy varied between 1 % and 73.4 %. The pooled prevalence was 16.7 %, 95 % CI = (15.6 %; 17.8 %). The hospital mortality was higher in patients with thoracic lymphadenopathy (34.7 %) than in patients without (20.0 %). The pooled odds ratio for the influence of thoracic lymphadenopathy on mortality was 2.13 (95 % CI = [1.80-2.52], p < 0.001). CONCLUSION:  The prevalence of thoracic lymphadenopathy in COVID-19 is 16.7 %. The presence of thoracic lymphadenopathy is associated with an approximately twofold increase in the risk for hospital mortality in COVID-19. KEY POINTS:   · The prevalence of lymphadenopathy in COVID-19 is 16.7 %.. · Patients with lymphadenopathy in COVID-19 have a higher risk of mortality during hospitalization.. · Lymphadenopathy nearly doubles mortality and plays an important prognostic role.. CITATION FORMAT: · Bucher AM, Sieren M, Meinel F et al. Prevalence and prognostic role of thoracic lymphadenopathy in Covid-19. Rofo 2025; 197: 163 - 171.

Involved external institutions

How to cite

APA:

Sähn, M.J., Wienke, A., Meyer, H.J., Dietz, J., Vogl, T.J., Borggrefe, J.,... Wohlgemuth, W. (2025). Prevalence and prognostic role of thoracic lymphadenopathy in Covid-19. Röfo: Fortschritte auf dem Gebiet der Röntgenstrahlen und der bildgebenden Verfahren, 197(2), 163-171. https://doi.org/10.1055/a-2293-8132

MLA:

Sähn, Marwin Jonathan, et al. "Prevalence and prognostic role of thoracic lymphadenopathy in Covid-19." Röfo: Fortschritte auf dem Gebiet der Röntgenstrahlen und der bildgebenden Verfahren 197.2 (2025): 163-171.

BibTeX: Download